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Artemisia annua L., a medicinal herb, produces secondary metabolites with antimicrobial property. In Malaysia due to the tropical
hot climate, A. annua could not be planted for production of artemisinin, the main bioactive compound. In this study, the leaves of
three in vitro A. annua L. clones were, extracted and two bioactive compounds, artemisinin and a precursor, were isolated by thin
layer chromatography. These compounds were found to be effective in inhibiting the growth of Gram-positive and Gram-negative
bacteria but not Candida albicans. Their antimicrobial activity was similar to that of antibactericidal antibiotic streptomycin. They
were found to inhibit the growth of the tested microbes at the minimum inhibition concentration of 0.09mg/mL, and toxicity test
using brine shrimp showed that even the low concentration of 0.09mg/mL was very lethal towards the brine shrimps with 100%
mortality rate. This study hence indicated that in vitro cultured plantlets of A. annua can be used as the alternative method for
production of artemisinin and its precursor with antimicrobial activities.
1. Introduction
Artemisia annua L., an annual medicinal herb, can be found
growing wild in the temperate and high altitude regions of
China and Vietnam [1, 2]. Traditionally it is used to allevi-
ate high fever and treatment of jaundice [3]. Artemisinin,
one of the bioactive compounds, with antimalarial activity
has been successfully isolated from A. annua [4]. Other
than antimalarial activity, artemisinin was found to be a
good antibacterial, antifungal, antileishmanial, and antitu-
mor agent. The antibacterial properties of artemisinin had
been tested on a wide range of bacteria, such as Escherichia
coli [5], Staphylococcus aureus, Pseudomonas aeruginosa, and
Mycobacterium intracellulare [6]. A broad spectrum of other
secondary metabolites was found and accumulated at the
aerial part of A. annua. However, the secondary metabolite
contents are often influenced by environmental stresses [7, 8].
In Malaysia, the hot tropical weather delimits the planting of
this herb as crop plant, and thus in vitro culture technique
can be used as the alternative tool for the production of
artemisinin. However, secondary metabolites that are pro-
duced in vitro often differ in type and amount than those
produced in field cultivated plants due to biotic and abiotic
stresses [9, 10]. The focus of this paper was hence to report
whether the bioactive compounds derived from the leaves of
in vitro plantlets of A. annua possess antimicrobial activity
towards an array of bacteria and fungus of Malaysian local
isolates and also the toxicity level of these compounds on
brine shrimp. These toxicity assays [11] are used to assess the
toxicity level of the bioactive compounds derived from the in
vitro plantlets of A. annua.
2. Materials and Methods
2.1. Plant Material. Three different clones of A. annua L.
of Vietnam origin, TC1, TC2, and Highland, were estab-
lished from seeds and cultured on MS [12] medium. The
excised nodal segments from the eight weeks old seed-
derived in vitro plantlets were subsequently cultured on MS
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basal medium containing 30 g/L sucrose and 8 g of Agar
(Algas, Chile) for mass production of plant materials for the
present study. The in vitro plantlets were maintained under a
constant temperature of 25 ± 2∘C with continuous lighting
of approximately 32.5 𝜇molm−2 s−1 light intensity. The pH
of all the culture media used in this study was adjusted to
pH 5.7–5.8 before autoclaving (Tommy 325) at 121∘C for 11
minutes under 1.05 kg/cm2 pressure.Harvested plantlets were
air dried at room temperature until constant driedweight was
obtained.
2.2. Extraction and Fraction of Crude Extract. Dried aerial
parts (20 g) of the three different clones cultured on the MS
[12] medium were powdered with mortar and pestle. They
were extracted with n-hexane (AR grade) with the aid of
ultrasonication. The collected supernatants were evaporated
into dry extract using rotary evaporator. The crude extracts
were dissolved in a combination of acetonitrile (Sigma) and
n-hexane (Sigma) solvents and partitioned using a separation
funnel. The partitioned parts of solvents were tested for
artemisinin using thin layer chromatography (TLC). The
fraction with artemisinin was dried using rotary evaporator.
Then, the dried fractionwas weighed and purified via column
chromatography based on the method by El-Feraly et al. [13].
Fractions of 1mL were tested for presence of artemisinin,
and fractions that contained artemisinin and a precursor
located very near to artemisinin (tested via TLC) were then
pooled together and dried with rotary evaporator. It was
then purified again by eluting in column chromatography as
mentioned above. Fractions with artemisinin and a precursor
were pooled into a flask, respectively, and weighed.
2.3. Preparation of Bacterial and Fungal Cultures. Three
Gram-positive USM bacteria strains, Staphylococcus aureus,
Bacillus thuringiensis, and Bacillus subtilis, two Gram-
negative USM bacteria strains, Escherichia coli and
Salmonella sp., and Candida albicans (yeast, USM strain)
were used for antimicrobial activities studies. The bacterial
strains were grown inNutrient Agar (NA) plates and the yeast
was grown in Sabouraud Dextrose Agar (SDA) medium. All
microbial cultures were incubated at 37∘C while the stock
cultures were maintained at 4∘C.
2.4. Evaluation of Antimicrobial Activities
2.4.1. Antimicrobial Disk Diffusion Assay. Nutrient Agar
(NA) and Sabouraud Dextrose Agar (SDA) were prepared
and sterilized in a Schott bottle and cooled before poured
into sterilized petri dishes (diameter 9 cm). The bacteria and
yeast were then cultured on the solid plates with sterile cotton
bud. The filter paper (Whatman) discs with the diameter
of 0.6 cm were placed on the agar plates cultured with the
tested microorganisms. Filter paper discs impregnated with
1 𝜇L of acetonitrile and streptomycin were used as negative
and positive controls, respectively. Purified extracts were
impregnated on the filter paper discs accordingly. All the
plates were incubated at 37∘C for 48 h. The diameters of
the inhibition zones were measured every six hours during
the 48 h incubation period. All the tests were performed in
triplicate.
2.4.2. Minimum Inhibition Concentration (MIC) Measure-
ment. Minimum inhibition concentration (MIC) for each
microbe was determined based on the least concentrations of
artemisinin and precursor needed to inhibit the growth of the
tested microbes. A serial dilution of artemisinin and precur-
sorswas done so that the concentration of the artemisinin and
precursor was in range of 0.09mg/ml to 3mg/ml. Six disks
of all the six concentrations were impregnated on each plate
of tested microbes. The test was done in triplicates for each
compound derived from each clone.
2.4.3. Toxicity Test for Artemisinin and Precursor. Lethal con-
centration 50 (LC
50
) is themeasurement of the concentration
of an extract that kills half of the sampling population. The
two fractions of compounds (artemisinin and precursor)
obtained from the three clones were tested against brine
shrimps (Artemia salina). Brine shrimp was prepared by
hatching 50mg of eggs in artificial sea water (30 g/L NaCl).
The brine shrimp eggs were placed under constant lighting
for 24 hours. A serial dilution of the compounds was done
so that the concentration of the compounds was in range of
0.09mg/mL to 3mg/mL. The diluted compounds were then
transferred into 96-well microtiter plate. Ten brine shrimps
were loaded into each well containing the compounds. The
experiment was done in six replicates for each dilution factor
of a compound. The brine shrimps were incubated under
constant light at 30∘C for 24 hours. Artificial seawater was
used as control for each compound.
3. Results
3.1. Extraction of Artemisinin and Precursor from In Vitro A.
annua L. plantlets. The amount of crude extract obtained
from 20 g dried leaves of A. annua was found to be different
for each clone. The highest yield of crude extract could be
obtained from TC2 clone followed by the Highland and TC1
clones. The crude extracts were then fractioned and purified
by column chromatography. The results of column chro-
matography purification indicated that all the three tested
clones of in vitro A. annua plantlets contained between 2.90
and 3.75mg/g of artemisininwithHighland clone (3.75mg/g)
and TC2 clone (3.55mg/g) produced higher artemisinin as
compared to TC1 clone. Whereas the content of precursor
in the three clones of A. annua in vitro plantlets was in
the range of 1.85 and 3.9mg/g with TC2 clone produced
the highest precursor content (3.9mg/g) followed by TC1
clone (2.3mg/g) and the Highland (1.85mg/g) (Table 1).
These two compounds were identified and distinguished
from each other using thin layer chromatography (TLC)
through the comparison with artemisinin standard (98%
purity, Sigma).The precursor above artemisinin which could
be an artemisinin derivative was clearly separated from
artemisinin and very visible in all the extracts from the three
in vitro clones (Figure 1). These two compounds obtained
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Table 1: Yield of crude extract, artemisinin, and precursor from the dried leaves of three clones of A. annua.
A. annua clone Crude extract (mg/g) Artemisinin (mg/g) Precursor (mg/g)
TC1 16.65 2.90 2.30
TC2 19.70 3.55 3.90
Highland 17.90 3.75 1.85
Table 2: Antimicrobial activity of artemisinin (6mg/mL) isolated from three clones of A. annua L., streptomycin (6mg/mL) as positive




TC1 TC2 Highland Streptomycin (positive ) Acetonitrile (negative)
Bacillus subtilis 1 ± 0.41a 1 ± 0.82a 1 ± 0.82a 1 ± 0.41a 0 ± 0.00b
Staphylococcus aureus 2 ± 1.15a 3 ± 1.58a 3 ± 1.58a 3 ± 2.24a 0 ± 0.00b
Bacillus thuringiensis 1 ± 0.00a 1 ± 0.00a 1 ± 0.00a 1 ± 0.00a 0 ± 0.00b
Escherichia coli 0 ± 0.00b 0 ± 0.00b 0 ± 0.00b 3 ± 0.00a 0 ± 0.00b
Salmonella sp. 1 ± 0.00a 2 ± 1.29a 1 ± 0.00a 1 ± 0.00a 0 ± 0.00b
Candida albicans 0 ± 0.00b 0 ± 0.00b 0 ± 0.00b 10 ± 0.82a 0 ± 0.00b
Values are mean inhibition zone (mm) ± SD of three replicates.
Mean values of inhibition zones of each microorganism followed by the same alphabet were not significantly different (Tukey test, 𝑃 ≤ 0.05).
Standard TC1 TC2 Highland
Artemisinin
Precursor
Figure 1: Thin layer chromatography (TLC). Purple band denotes
precursor and pink band denotes artemisinin compounds which
were purified separately by column chromatography and used for
the antimicrobial screening and toxicity test.
from each A. annua clone were used for the subsequent
antimicrobial screening and toxicity tests.
3.2. Evaluation of Antimicrobial Effect of Artemisinin and
Precursor and Determination of MIC Value. A preliminary
antimicrobial screening test using disk diffusion technique
was done on locally isolated six microorganisms consisted of
Gram-positive and negative strains bacteria and one fungus.
Artemisinin and precursor were tested on three Gram-
positive strains, Staphylococcus aureus, Bacillus thuringiensis,
and Bacillus subtilis, two Gram-negative strains, Escherichia
coli and Salmonella sp., and a yeast strain, Candida albicans.
Among all the tested microbes, artemisinin of the three A.
annua clones was most effective on S. aureus with TC2 and
Highland having the same inhibition zone (3 ± 1.58mm) as
that of streptomycin (positive control). TC1 clone which has
inhibition zone of 2 ± 1.15mmwas not significantly different
from the positive control. This indicated that artemisinin
could be an effective anti-S. aureus drug. B. subtilis and
B. thuringiensis showed inhibition zone of 1 ± 0.00mm
when treated with artemisinin derived from the three clones.
This also showed that artemisinin could be an antimicro-
bial drug against Gram-positive bacteria. Between the two
tested Gram-negative strains, only Salmonella sp., showed
inhibition growth due to artemisinin derived from the three
clones, and their anti-Salmonella activities were similar to
that of streptomycin, the positive control. Artemisinin from
the three clones did not exhibit any antimicrobial activity on
E. coli and C. albicans (Table 2).
Precursor from all the three clones showed antimicrobial
effect towards both the Gram-positive and Gram-negative
bacteria except the yeast, C. albicans. Precursor derived from
TC1 showed the strongest effect on E. coli, and this was not
significantly different from that of streptomycin, the positive
control.The anti-E. coli activity was in the order of TC1>TC2
> Highland. This indicated that precursors from the three
clones were effective as anti-bacteria for both Gram-positive
and Gram-negative. On the other hand, precursor did not
inhibit the growth of C. albicans (Table 3).
From this preliminary antimicrobial assay, the growth
of the three bacteria strains (B. subtilis, S. aureus, and
Salmonella sp.) was inhibited by both artemisinin and its pre-
cursor; hence they were chosen for the minimum inhibitory
concentration (MIC) assay. MIC assay was done to deter-
mine the lowest concentration of compounds that inhibits
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Table 3: Antimicrobial activity of precursor (6mg/mL) isolated from three clones ofA. annua L., streptomycin (6mg/mL) as positive control




TC1 TC2 Highland Positive Negative
Bacillus subtilis 1 ± 0.89a 1 ± 0.63a 1 ± 0.63a 1 ± 2.23a 0 ± 0.00b
Staphylococcus aureus 3 ± 2.41a 2 ± 1.18a 3 ± 1.40a 3 ± 2.28a 0 ± 0.00b
Bacillus thuringiensis 1 ± 0.00a 1 ± 0.00a 1 ± 0.0a 1 ± 0.58a 0 ± 0.00b
Escherichia coli 3 ± 0.00a 2 ± 0.00b 1 ± 0.00c 3 ± 0.00a 0 ± 0.00d
Salmonella spp. 1 ± 0.00a 1 ± 0.50a 1 ± 0.50a 1 ± 0.00a 0 ± 0.00b
Candida albicans 0 ± 0.00b 0 ± 0.00b 0 ± 0.00b 10 ± 1.08a 0 ± 0.00b
Values are mean inhibition zone (mm) ± SD of three replicates.
Mean values of inhibition zones of each microorganism followed by the same alphabet were not significantly different (Tukey test, 𝑃 ≤ 0.05).
Table 4: Minimum inhibitory concentration (MIC) value of artemisinin and its precursor derived from the threeA. annua clones on selected
microorganism.
Microorganisms
Minimum inhibition concentration (MIC) in mg/mL
TC1 clone TC2 clone Highland clone
Precursor Artemisinin Precursor Artemisinin Precursor Artemisinin
Bacillus subtilis 0.09 0.09 0.09 0.09 0.09 0.09
Staphylococcus aureus 0.09 0.09 0.09 0.09 0.09 0.09
Salmonella sp. 0.09 0.09 0.09 0.09 0.09 0.09
the microbial growth. The result of MIC on the three tested
microbes indicated that the lowest concentration of both
artemisinin and its precursor derived from the three clones,
TC1, TC2, andHighlandwas, 0.09mg/mLwhichwas effective
to inhibit all the growth of the three testedmicrobes (Table 4).
3.3. Toxicity Study of Artemisinin and Precursor. Toxicity
test of artemisinin and precursor from the three in vitro A.
annua L. clones on brine shrimp showed that inhibition of
brine shrimp growth still occurred even at the lowest tested
concentration (0.09mg/mL) of the compounds. Within one
hour of incubation, the brine shrimpswere all dead indicating
high toxicity level of artemisinin and precursor against brine
shrimp growth, and thus LC
50
could not be determined.
4. Discussion
The antimicrobial effects of artemisinin and precursor
extracted from in vitro plantlets of A. annua were tested
on the chosen six microbes which causes illness in human
[14–16]. Results obtained indicated that artemisinin and
its precursor were effective against Gram-positive bacteria,
and their antibacterial activities were similar to that of
streptomycin, a bactericidal antibiotic. Plant extracts from
Asteraceae family against Gram-positive strain bacteria had
been reported previously [17–21]. Artemisinin derived from
field grownA. annua plants was also reported to have antimi-
crobial activity [22–24]. The susceptibility activity of Gram-
positive strains to artemisinin and precursor derived from in
vitro A. annua plantlets which had not been reported before
confirmed that the in vitro plantlets could produce bioactive
compounds that were similar to that found in the field grown
mature plants of A. annua. These artemisinin and precursor
produced from the in vitro plantlets also possess antimicro-
bial activity comparable to streptomycin. Hence, the present
study indicated that the in vitro plantlets ofA. annua could be
used as an alternative mean for the production of artemisinin
and its precursor in tropical countries like Malaysia as A.
annua cannot be grown in the constantly hot tropical weather
[25]. Moreover, the artemisinin and its precursor produced
from the in vitro plantlets are effective towards the Gram-
positive strains bacteria at a low concentration (0.09mg/mL)
as indicated by the MIC results. The susceptibility of Gram-
positive strains towards photochemical compounds derived
from A. annua was caused by the inhibition of the efflux
pump in the bacteria [26].
Gram-negative strains used in this study were Salmonella
sp. and E. coli. The artemisinin derived from the in vitro
plantlets of A. annua was only effective for Salmonella sp.
but not the E. coli. However the precursor was effective
against both Gram-negative bacteria especially the E. coli.
The resistance of Gram-negative strain towards artemisinin
suggested that these bacteria have multidrug resistance due
to the presence of active multiefflux pumps. This active
multiefflux pump of inhibitory substance is a very important
part of the antimicrobial compound defence in bacteria [27].
The permeability of cell walls of Gram-negative and Gram-
positive bacteria differs greatly in terms of the rate of large
molecules penetrations [28]. This was one of the reasons
Gram-negative bacteria were more resistant to antimicrobial
compounds which supported the findings of this study.
However, the precursor in this study was found to be more
effective in growth inhibition of E. coli bacteria compared
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to artemisinin. Isolated plant compounds which reported
to have antibacterial property against Gram-positive strains
normally do not work likewise for Gram-negative strain [29].
The susceptibility of E. coli to the precursor derived from
the A. annua in vitro plantlets suggested that this compound
was coextracted with fatty acids which successfully inhibited
the efflux pumps in E. coli [30]. The result obtained from
this study further confirmed the inability of artemisinin and
precursor to inhibit C. albicans as reported by Galal et al.
[22] that artemisinin and its derivatives were not effective
for inhibiting the growth of C. albicans and Cryptococcus
neoformans.
Minimum inhibitory concentration (MIC) value for both
artemisinin and its precursor derived from the in vitro
plantlets of three A. annua clones showed that a very
low concentration (0.09mg/mL) was sufficient to inhibit
the growth of Bacillus subtilis and Staphylococcus aureus
(Gram-positive bacteria) and Salmonella sp. (Gram-negative
bacteria). Nagshetty et al. [31] reported that three antibiotics,
Nalidixic acid, Ampicillin, and Chloramphenicol, had MIC
values in the range of 32–256𝜇g/mL while the MIC value
for Ciprofloxacin was achieved in the range of 0.125–4𝜇g/mL
towards Salmonella typhi. This indicated that different antibi-
otics have different antimicrobial capability. Some require
much higher concentration whereas very low concentration
of Ciprofloxacin, normally used in very purified form, was
needed to inhibit the growth of S. typhi when compared
to the artemisinin and precursor (90 𝜇g/mL) derived from
the tissue cultured plantlets of A. annua used in this study.
While artemisinin of 9mg/mL derived from the field grown
plants was needed to inhibit malaria causing Plasmodium
falciparum [32]. The result obtained from our study on the
brine shrimp toxicity test suggested that artemisinin and pre-
cursor could be very toxic when used at high concentration
because as low as 0.09mg/mL of both the artemisinin and
its precursor caused high mortality rate (100%) of the brine
shrimp.
5. Conclusion
The antimicrobial activity of artemisinin and precursor
derived from the in vitro plantlets of A. annua was found
to be having antimicrobial capability as that of the commer-
cially available antibiotic, streptomycin. The ability to inhibit
microbial growth suggested that in vitro cultured A. annua
could be an alternative for the production of these potential
antimicrobial drugs.
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